<DrugInformationSummary id="CDR0000764622"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Pembrolizumab works by binding to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack the cancer cells. Pembrolizumab is a type of immunotherapy drug called an immune checkpoint inhibitor.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab">Pembrolizumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000695789">pembrolizumab</TerminologyLink><GlossaryLink ref="CDR0000764538">pembrolizumab</GlossaryLink><USBrandNames><USBrandName>Keytruda</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>pem-broh-LIH-zoo-mab</TermPronunciation><MediaLink ref="CDR0000766721" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000766720" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Pembrolizumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Pembrolizumab
         is approved 
         to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000559456" dictionary="Cancer.gov" audience="Patient">Biliary tract</GlossaryTermRef> cancer</Strong> that has spread or cannot be removed by surgery.  It is used with <GlossaryTermRef href="CDR0000508951" dictionary="Cancer.gov" audience="Patient">gemcitabine hydrochloride</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000639916" dictionary="Cancer.gov" audience="Patient">triple negative</GlossaryTermRef>. Pembrolizumab is used:<ItemizedList Style="bullet" id="_16"><ListItem>with chemotherapy in patients whose cancer has the <GlossaryTermRef href="CDR0000797389" dictionary="Cancer.gov" audience="Patient">PD-L1</GlossaryTermRef> protein and has come back and cannot be removed by surgery or has spread</ListItem><ListItem>with chemotherapy before surgery and then alone after surgery in patients with <GlossaryTermRef href="CDR0000561398" dictionary="Cancer.gov" audience="Patient">early-stage cancer</GlossaryTermRef> that has a  <GlossaryTermRef href="CDR0000045079" dictionary="Cancer.gov" audience="Patient">high risk</GlossaryTermRef> of coming back</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444973" dictionary="Cancer.gov" audience="Patient">Cervical cancer</GlossaryTermRef>.</Strong> Pembrolizumab is used:<ItemizedList Style="bullet" id="_17"><ListItem>with chemotherapy and radiation therapy in patients with
<GlossaryTermRef href="CDR0000045888" dictionary="Cancer.gov" audience="Patient">stage III</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045889" dictionary="Cancer.gov" audience="Patient">stage IVA cervical cancer</GlossaryTermRef></ListItem><ListItem>with chemotherapy, with or without <GlossaryTermRef href="CDR0000046115" dictionary="Cancer.gov" audience="Patient">bevacizumab</GlossaryTermRef>, in patients whose cancer has the PD-L1 protein and did not respond to treatment, has come back, or has spread to other parts of the body</ListItem><ListItem>alone in patients whose cancer has the PD-L1 protein, has come back or spread to other parts of the body, and has gotten worse during or after chemotherapy</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000574284" dictionary="Cancer.gov" audience="Patient">Classic Hodgkin lymphoma</GlossaryTermRef>.</Strong> Pembrolizumab is used:<ItemizedList Style="bullet" id="_14"><ListItem>in adults whose cancer   does not respond to treatment or has <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef></ListItem><ListItem>in children whose cancer is refractory or has relapsed after at least two other types of treatment</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000795104" dictionary="Cancer.gov" audience="Patient">Cutaneous squamous cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000445084" dictionary="Cancer.gov" audience="Patient">skin cancer</GlossaryTermRef>) that has spread or come back. Pembrolizumab is used in patients whose cancer cannot be cured  with surgery or <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444987" dictionary="Cancer.gov" audience="Patient">Endometrial carcinoma</GlossaryTermRef></Strong>  in adults. Pembrolizumab is used:<ItemizedList Style="bullet" id="_20"><ListItem>with <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> and then alone in patients with cancer that has spread or has come back</ListItem><ListItem>with <GlossaryTermRef href="CDR0000769612" dictionary="Cancer.gov" audience="Patient">lenvatinib</GlossaryTermRef> in patients with cancer that is not <GlossaryTermRef href="CDR0000285933" dictionary="Cancer.gov" audience="Patient">microsatellite instability</GlossaryTermRef>-high (MSI-H) or <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR),  has  gotten worse after other <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapies</GlossaryTermRef>, and cannot be cured  with surgery or radiation therapy</ListItem><ListItem>alone in patients with cancer that is MSI-H or dMMR, cannot be cured  with surgery or radiation therapy, and has gotten worse after other systemic therapies</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444989" dictionary="Cancer.gov" audience="Patient">Esophageal</GlossaryTermRef></Strong> or<Strong> <GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> cancer</Strong> that has spread and cannot be cured <GlossaryTermRef href="CDR0000318813" dictionary="Cancer.gov" audience="Patient"/>  with surgery or a combination of chemotherapy and radiation therapy. Pembrolizumab is used:<ItemizedList Style="bullet" id="_15"><ListItem>with <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy and a <GlossaryTermRef href="CDR0000386207" dictionary="Cancer.gov" audience="Patient">fluoropyrimidine</GlossaryTermRef></ListItem><ListItem>alone in patients with <GlossaryTermRef href="CDR0000046595" dictionary="Cancer.gov" audience="Patient">squamous cell cancer</GlossaryTermRef> that has the PD-L1 protein and has been treated with  systemic therapy</ListItem></ItemizedList> </ListItem>   <ListItem><Strong><GlossaryTermRef href="CDR0000454513" dictionary="Cancer.gov" audience="Patient">Gastric (stomach) cancer</GlossaryTermRef></Strong> or <Strong><GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216" dictionary="Cancer.gov" audience="Patient">adenocarcinoma</GlossaryTermRef></Strong>   that has spread or cannot be treated with surgery. Pembrolizumab is used as the first treatment with: <ItemizedList Style="bullet" id="_21"><ListItem><GlossaryTermRef href="CDR0000045439" dictionary="Cancer.gov" audience="Patient">trastuzumab</GlossaryTermRef>, a fluoropyrimidine, and platinum-based chemotherapy in patients whose cancer has the PD-L1 protein and is <GlossaryTermRef href="CDR0000737998" dictionary="Cancer.gov" audience="Patient">HER2 positive</GlossaryTermRef></ListItem><ListItem>fluoropyrimidine and platinum-based chemotherapy in patients whose cancer is <GlossaryTermRef href="CDR0000774531" dictionary="Cancer.gov" audience="Patient">HER2 negative</GlossaryTermRef></ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">Hepatocellular carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000044242" dictionary="Cancer.gov" audience="Patient">liver cancer</GlossaryTermRef>) in patients who have been treated with <GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">sorafenib</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">Melanoma</GlossaryTermRef></Strong>.  Pembrolizumab is used in:<ItemizedList Style="bullet" id="_9"><ListItem>patients whose cancer cannot be removed by surgery or has spread to other parts of the body </ListItem><ListItem>  adults and children aged 12 years and older 
with  <GlossaryTermRef href="CDR0000045137" dictionary="Cancer.gov" audience="Patient">stage IIB</GlossaryTermRef>, stage IIC, or <GlossaryTermRef href="CDR0000045138" dictionary="Cancer.gov" audience="Patient">stage III melanoma</GlossaryTermRef> to prevent the cancer from coming back after it has been removed by surgery</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000044323" dictionary="Cancer.gov" audience="Patient">Malignant pleural mesothelioma</GlossaryTermRef>.</Strong> Pembrolizumab is given with pemetrexed and platinum chemotherapy as the first
treatment in adults whose cancer has spread or cannot be removed by surgery.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000658511" dictionary="Cancer.gov" audience="Patient">Merkel cell carcinoma</GlossaryTermRef></Strong> in adults and children.  Pembrolizumab is used in patients whose cancer has come back or spread.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000285933" dictionary="Cancer.gov" audience="Patient">Microsatellite instability</GlossaryTermRef>-high (MSI-H) or <GlossaryTermRef href="CDR0000789741" dictionary="Cancer.gov" audience="Patient">mismatch repair deficient</GlossaryTermRef> (dMMR) cancer</Strong> that is has spread to other parts of the body or cannot be removed by surgery. Pembrolizumab is used to treat:<ItemizedList Style="bullet" id="_6"><ListItem><GlossaryTermRef href="CDR0000045301" dictionary="Cancer.gov" audience="Patient">solid tumors</GlossaryTermRef> in adults and children that  got worse after other treatment   and cannot be treated with other therapies</ListItem><ListItem><GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">colorectal cancer</GlossaryTermRef></ListItem></ItemizedList><Para id="_7">MSI-H and dMMR cancers have certain <GlossaryTermRef href="CDR0000046391" dictionary="Cancer.gov" audience="Patient">genetic</GlossaryTermRef> <GlossaryTermRef href="CDR0000046063" dictionary="Cancer.gov" audience="Patient">mutations</GlossaryTermRef> and may not respond to some types of treatment.</Para></ListItem>
   
   <ListItem><Strong><GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">Non-small cell lung cancer</GlossaryTermRef>.</Strong> Pembrolizumab is used:<ItemizedList Style="bullet" id="_5"><ListItem>with <GlossaryTermRef href="CDR0000045456" dictionary="Cancer.gov" audience="Patient">pemetrexed</GlossaryTermRef> and platinum-based chemotherapy as the first treatment in patients with nonsquamous cancer that has spread to other parts of the body and does not have a mutation in the <GeneName><GlossaryTermRef href="CDR0000796876" dictionary="Cancer.gov" audience="Patient">EGFR</GlossaryTermRef></GeneName> gene or <GeneName><GlossaryTermRef href="CDR0000721252" dictionary="Cancer.gov" audience="Patient">ALK</GlossaryTermRef></GeneName> gene</ListItem><ListItem>with carboplatin and either paclitaxel or <GlossaryTermRef href="CDR0000507600" dictionary="Cancer.gov" audience="Patient">paclitaxel albumin-stabilized nanoparticle formulation</GlossaryTermRef> as the first treatment for <GlossaryTermRef href="CDR0000046056" dictionary="Cancer.gov" audience="Patient">squamous</GlossaryTermRef> cancer that has spread to other parts of the body</ListItem><ListItem>with platinum-based chemotherapy before surgery and then alone as <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef>, to help keep the cancer from coming back after surgery</ListItem><ListItem>alone as the first treatment in patients with cancer that has the PD-L1 protein, does not have a mutation in the <GeneName>EGFR</GeneName> gene or <GeneName>ALK</GeneName> gene, and is either stage III and cannot be treated with surgery or <GlossaryTermRef href="CDR0000306495" dictionary="Cancer.gov" audience="Patient">chemoradiation</GlossaryTermRef> or has spread to other parts of the body</ListItem><ListItem>alone in patients with cancer that has spread to other parts of the body, has the PD-L1 protein, and has gotten worse during or after treatment with platinum-based chemotherapy; if the cancer has <GeneName>EGFR</GeneName> or <GeneName>ALK</GeneName> gene mutations, patients must have received <GlossaryTermRef href="CDR0000532303" dictionary="Cancer.gov" audience="Patient">EGFR inhibitor</GlossaryTermRef> or <GlossaryTermRef href="CDR0000795666" dictionary="Cancer.gov" audience="Patient">ALK inhibitor</GlossaryTermRef> therapy and it did not work or is no longer working</ListItem><ListItem>alone in adults with <GlossaryTermRef href="CDR0000682415" dictionary="Cancer.gov" audience="Patient">stage IB</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045357" dictionary="Cancer.gov" audience="Patient">stage IIA</GlossaryTermRef>, <GlossaryTermRef href="CDR0000682419" dictionary="Cancer.gov" audience="Patient">stage IIB</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045367" dictionary="Cancer.gov" audience="Patient">stage IIIA</GlossaryTermRef> cancer, to help keep the cancer from coming back after platinum-based chemotherapy and surgery</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000777025" dictionary="Cancer.gov" audience="Patient">Primary mediastinal large B-cell lymphoma</GlossaryTermRef>.</Strong> Pembrolizumab is used in adults and children whose cancer does not respond to treatment or has returned after at least two other therapies.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">Renal cell carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444995" dictionary="Cancer.gov" audience="Patient">kidney cancer</GlossaryTermRef>). It is used:<ItemizedList Style="bullet" id="_19"><ListItem>with <GlossaryTermRef href="CDR0000538635" dictionary="Cancer.gov" audience="Patient">axitinib</GlossaryTermRef> or lenvatinib as the first treatment in patients whose cancer has spread or cannot be removed by surgery</ListItem><ListItem>as adjuvant therapy in patients whose cancer has a high risk of coming back after surgery to remove the kidney or surgery to remove the kidney and metastatic cancer</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045301" dictionary="Cancer.gov" audience="Patient">Solid tumors</GlossaryTermRef></Strong> that are <GlossaryTermRef href="CDR0000795825" dictionary="Cancer.gov" audience="Patient">tumor mutational burden</GlossaryTermRef>-high (TMB-H) and  have spread to other parts of the body or cannot be removed by surgery. Pembrolizumab is used in adults and children whose cancer got worse after treatment and who are not able to receive other therapies.¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000597171" dictionary="Cancer.gov" audience="Patient">Squamous cell carcinoma of the head and neck</GlossaryTermRef></Strong> that has come back or has spread to other parts of the body. Pembrolizumab is used:<ItemizedList Style="bullet" id="_12"><ListItem>with platinum-based chemotherapy and <GlossaryTermRef href="CDR0000046090" dictionary="Cancer.gov" audience="Patient">fluorouracil</GlossaryTermRef> as the first treatment in patients whose cancer cannot be removed by surgery</ListItem><ListItem>alone as the first treatment in patients whose cancer cannot be removed by surgery and whose tumors have the PD-L1 protein</ListItem><ListItem>alone in patients whose cancer got worse during or after treatment with platinum-based chemotherapy</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000783188" dictionary="Cancer.gov" audience="Patient">Urothelial carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000444968" dictionary="Cancer.gov" audience="Patient">bladder cancer</GlossaryTermRef>).  Pembrolizumab is used:<ItemizedList Style="bullet" id="_8"><ListItem>with <GlossaryTermRef href="CDR0000800193" dictionary="Cancer.gov" audience="Patient">enfortumab vedotin</GlossaryTermRef> in adults whose cancer has spread</ListItem><ListItem>alone in patients whose cancer has spread and cannot be treated with platinum-based chemotherapy or  has gotten worse during or after treatment with platinum-based chemotherapy</ListItem><ListItem>alone in patients with <GlossaryTermRef href="CDR0000046488" dictionary="Cancer.gov" audience="Patient">carcinoma in situ</GlossaryTermRef>, a type of bladder cancer that has not spread to the bladder muscle but is at high risk of spreading, that did not respond to treatment with <GlossaryTermRef href="CDR0000746944" dictionary="Cancer.gov" audience="Patient">bacillus Calmette-Guérin</GlossaryTermRef> (BCG), when surgery is not an option for health or personal reasons</ListItem></ItemizedList> </ListItem></ItemizedList>
  
 <Para id="_11">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that pembrolizumab provides a clinical benefit in these patients.</Para><Para id="_4">Pembrolizumab is also being studied in the treatment of other types of cancer. </Para></Section><Section id="_About"><Title>More About Pembrolizumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/695789">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.106">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a614048.html">Pembrolizumab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.107"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.108">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy">More Immunotherapy Options Approved for Treating Endometrial Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/kidney-cancer-pembrolizumab-increases-survival">Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/bladder-cancer-padcev-keytruda-doubles-survival">Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder Cancer Effects</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-pembrolizumab-stomach-esophageal-her2-pdl1">FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-mismatch-repair-biomarker">A Better Biomarker for Cancer Immunotherapy?</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors">Immune Checkpoint Inhibitors</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C106432">Find Clinical Trials for Pembrolizumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2014-09-18</DateFirstPublished><DateLastModified>2025-03-20</DateLastModified></DrugInformationSummary>
